Keywords: Sanofi-Aventis, Lixisenatide, Proteome Sciences, Type 2 diabetes, Ph III, Settlement, Zealand Pharma
Sanofi-Aventis presents strong date for once-daily lixisenatide in combination with basal insulin; settles with Proteome
Article | 01 October 2010
French drug major Sanofi-Aventis (Euronext: SAN) has announced the top-line results of the Phase III GETGOAL-L-ASIA study assessing the efficacy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
